Core Viewpoint - The article emphasizes the importance of distinguishing between common colds and sinusitis, especially during the winter season when respiratory diseases are prevalent. Early identification and intervention can lead to effective treatment and recovery from sinusitis, which can develop from untreated colds. Group 1: Winter Respiratory Diseases - Winter conditions such as low temperatures and dry air weaken nasal mucosal resistance, making it easier for viruses to cause colds, which can lead to sinusitis due to blocked nasal passages and bacterial growth [2] - The presence of smog and dust in winter can further irritate the nasal and sinus mucosa, exacerbating inflammation and creating a cycle of worsening symptoms [2] Group 2: Symptoms and Differentiation - Key differences between a common cold and sinusitis include the duration and location of symptoms: colds are acute viral infections of the nasal mucosa, while sinusitis involves inflammation of the sinus cavities, often developing from untreated colds [3] - Symptoms lasting more than 7 days or worsening after initial improvement are strong indicators of sinusitis [3][4] - Typical signs of sinusitis include yellow-green nasal discharge, localized headaches, and a decrease in smell, which can help differentiate it from a common cold [5][6] Group 3: Treatment and Home Care - Home care strategies include saline nasal irrigation, which can provide temporary relief for colds but is less effective for sinusitis [7] - Short-term use of decongestants can alleviate nasal congestion for colds but may worsen sinusitis symptoms [8] - A three-step home assessment process is recommended: saline irrigation, short-term decongestant use, and considering nasal steroids if symptoms persist beyond 7 days [9] Group 4: When to Seek Medical Attention - Immediate medical attention is necessary if symptoms persist for over 10 days, if there is a high fever, severe headaches, or signs of complications such as ear pain or difficulty breathing [10] - Diagnostic procedures may include nasal endoscopy and CT scans to assess the severity and type of sinusitis [10][11]

Core Viewpoint - Changfeng Pharmaceutical (02652) has received acceptance for its application for the marketing authorization of Budesonide nasal spray from the National Medical Products Administration of the People's Republic of China [1] Product Pipeline - The nasal spray is a complex formulation with high technical barriers, and the company has established a comprehensive product matrix covering various indications and full-course management of respiratory and rhinitis conditions [1] - Existing products in the company's portfolio include: - Fluticasone furoate nasal spray (Shu Fei Min): The first antihistamine-steroid combination nasal spray in China, included in the National Medical Insurance Drug List in 2023 [1] - Mometasone furoate nasal spray: A first-line medication for allergic rhinitis in adults and children aged 3 and above [1] - Budesonide nasal spray (the product in question): Suitable for patients aged 6 and above, targeting seasonal acute episodes, perennial maintenance treatment, and nasal polyps [1] - Olopatadine/Mometasone nasal spray: For moderate to severe allergic rhinitis symptoms in adolescents aged 12 and above and adults [1] Strategic Intent - The acceptance of the Budesonide nasal spray application further enriches the company's product pipeline in the allergic rhinitis field, demonstrating the company's commitment and capability to deepen its layout in the respiratory inhalation treatment sector, providing quality treatment options for patients [1] - The company will actively communicate with the NMPA and advance subsequent review procedures according to regulatory requirements [1]

Core Viewpoint - Changfeng Pharmaceutical's application for the marketing authorization of Budesonide nasal spray has been accepted by the National Medical Products Administration of China, indicating the company's commitment to expanding its product pipeline in the field of allergic rhinitis and respiratory treatments [1] Product Pipeline - The company has established a comprehensive product matrix covering various indications and full-course management of respiratory and rhinitis conditions, leveraging its nasal drug delivery technology platform [1] - Existing products in the company's portfolio include: - Azelastine/Fluticasone nasal spray (Shu Fei Min®): The first antihistamine-steroid combination nasal spray in China, included in the National Medical Insurance Drug List in 2023 [1] - Mometasone nasal spray: A first-line medication for allergic rhinitis in adults and children aged 3 and above [1] - Budesonide nasal spray: Targeted for patients aged 6 and above, addressing seasonal acute episodes, perennial maintenance treatment, and nasal polyps [1] - Olopatadine/Mometasone nasal spray: Designed for adolescents aged 12 and above and adults with moderate to severe allergic rhinitis symptoms [1] Strategic Commitment - The acceptance of the Budesonide nasal spray application further enriches the company's product pipeline in the allergic rhinitis sector, demonstrating its determination and capability to deepen its presence in the respiratory inhalation treatment field [1] - The company will actively communicate with the NMPA and advance subsequent review procedures in accordance with regulatory requirements [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CF PharmTech, Inc. 長風藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 自願公告 NMPA受理布地奈德鼻噴霧劑上市許可申請 本公告乃由長風藥業股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願作出，以知會股東及潛在投資者有關本集團之最新研發進展。 緒言 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司布地奈德鼻噴霧劑（「該 產品」）的上市許可申請（「申請」）已獲中華人民共和國國家藥品監督管理局 （「NMPA」）受理。茲公告相關資訊如下： 1 產品名稱 : 布地奈德鼻噴霧劑 申請類型 : 上市許可申請 受理號 : CYHS2600272/CYHS2600273 申請人 ： 本公司 規格 : 每噴32微克（每瓶120噴）╱每噴64微克（每瓶 120噴） 適應症 ： 治療(1)季節性及常年性過敏性鼻炎；(2)常年性 非過敏性鼻炎；及(3 ...

Policy Trends - Recent COVID-19 infections show a slight increase in some regions, but the clinical severity has not changed significantly according to a Chinese CDC expert [2] Drug and Device Approvals - Changshan Pharmaceutical's nadroparin calcium injection has received a drug registration certificate from Belarus, used for treating venous thromboembolism and other related conditions [3] - Shanghai Pharmaceuticals announced that its rivaroxaban tablets have received approval from the US FDA, aimed at reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, among other uses [4] Capital Markets - Shanghai Kejun Pharmaceutical Technology Co., Ltd. completed a B+ round financing exceeding 100 million yuan, with funds primarily allocated for the phase III clinical development of its core product CG-0255 in the cardiovascular field [5] Industry Developments - Jingyin Pharmaceutical and CRISPR Therapeutics have formed a strategic partnership to jointly develop and commercialize a long-acting siRNA therapy for thrombotic diseases [6] - Buchang Pharmaceutical's subsidiary signed a commissioned research agreement with Fubicheng Pharmaceutical for the development of MF59 adjuvant [7] - Sanofi and Pfizer entered into a licensing agreement for a bispecific antibody product targeting PD-1 and VEGF, with Pfizer gaining exclusive rights outside mainland China [9] Public Sentiment Alerts - Jinhua Co., Ltd. reported that shareholder Xinyu Jinyu has reduced its holdings by 133,500 shares, representing 0.035765% of the company's total share capital [10] - Fosun Pharma announced the resignation of its Senior Vice President Rong Yang for personal reasons, effective May 16, 2025 [11]

Group 1 - Shanghai Pharmaceuticals has received FDA approval for its abbreviated new drug application (ANDA) for Rivaroxaban tablets [1] - Rivaroxaban is indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1][2] - The company has invested approximately RMB 8.2 million in the research and development of Rivaroxaban [1] Group 2 - The market for Rivaroxaban in the U.S. generated approximately $8.13 billion in sales in 2023, with projected sales of about $6.33 billion for the first three quarters of 2024 [2] - Competitors in the U.S. market for Rivaroxaban include Janssen Pharmaceuticals and several generic manufacturers [2] Group 3 - The FDA has also approved the ANDA for Mometasone Furoate nasal spray by Zhejiang Xinyi Ruijue Pharmaceutical [4] - Mometasone Furoate is used for the prevention and treatment of seasonal allergic rhinitis in adolescents and adults, as well as for chronic sinusitis with nasal polyps in adults [5] - The nasal spray generated approximately $43.7 million in sales in the U.S. in 2023, with projected sales of about $33.45 million for the first three quarters of 2024 [5]

Core Viewpoint - The article discusses the significant impact of antitrust penalties on the financial performance of Xianju Pharmaceutical and other companies involved in price-fixing agreements for dexamethasone phosphate raw materials during the COVID-19 pandemic [1][3]. Group 1: Antitrust Penalties - Xianju Pharmaceutical was fined 195 million yuan for monopolistic practices, which accounts for 4.88% of its 2024 revenue and 49.17% of its net profit [1]. - Tianyao Pharmaceutical and Lianhuan Pharmaceutical were also penalized, with fines of 69.19 million yuan and 61.04 million yuan, respectively [1]. - The companies formed a price alliance, raising the price of dexamethasone phosphate from 0.35 yuan to a peak of 98.76 yuan, an increase of nearly 282 times [1]. Group 2: Financial Impact on Companies - In 2024, Xianju Pharmaceutical's net profit fell by 29.46% to 397 million yuan, largely due to the antitrust fine [2][4]. - The cash flow from operating activities for Xianju Pharmaceutical decreased by 33.05%, and cash reserves dropped by 16.76% [4]. - Tianyao Pharmaceutical's revenue in 2024 was 3.215 billion yuan, down 15%, but its net profit increased by 14% due to the fine being accounted for in 2025 [6][7]. Group 3: Market Adjustments and Strategies - Xianju Pharmaceutical is shifting its product structure and expanding into overseas markets to mitigate the impact of declining revenues from dexamethasone products [5]. - The company is focusing on high-margin areas such as respiratory and dermatological products, with sales in respiratory products growing by 31% in 2024 [5]. - Tianyao Pharmaceutical's steroid raw material business also saw a revenue decline of 16.9% in 2024, indicating broader market pressures [7]. Group 4: Ongoing Challenges - Tianyao Pharmaceutical has faced multiple antitrust penalties over the past four years, indicating a pattern of regulatory scrutiny [8]. - Lianhuan Pharmaceutical's future penalties remain uncertain as it plans to appeal the decision, highlighting the ongoing challenges within the industry [8].

Core Viewpoint - The announcement by the company regarding the approval of its fluticasone propionate nasal spray marks a significant step in breaking the market monopoly of foreign products in the domestic allergic rhinitis treatment sector [2]. Group 1: Product Development and Market Position - The fluticasone propionate nasal spray is the first domestic generic product to be launched in China and has been included in the national medical insurance and essential drug lists [2]. - The company has established itself as one of the leading firms in the domestic market for allergic rhinitis treatments, with a comprehensive product pipeline [2]. - The respiratory and critical care segment generated approximately HKD 1.71 billion in revenue last year, reflecting a nearly 27% year-on-year growth [2]. Group 2: Future Development Strategy - The company plans to continue its strategy of independent research and global expansion, focusing on developing a comprehensive product cluster for chronic airway diseases and critical care [3].

Core Viewpoint - The announcement of the approval of the fluticasone propionate nasal spray by Yuan Da Pharmaceutical marks a significant milestone for the company, as it is the first domestic generic version in China, expected to disrupt the market dominated by foreign products and provide more affordable treatment options for patients with allergic rhinitis [1][4]. Group 1: Market Opportunity - The fluticasone propionate nasal spray is a preferred treatment for allergic rhinitis in China, which has a high prevalence of approximately 17.6% among adults, translating to nearly 250 million patients [4][5]. - The nasal preparation market in China is projected to reach nearly 3.5 billion RMB in 2023, with a compound annual growth rate (CAGR) of 10.4% from 2019 to 2023 [4]. - The market for fluticasone propionate nasal spray is expected to reach 2.46 billion RMB by 2025, indicating substantial growth potential [4]. Group 2: Competitive Landscape - The current market for nasal corticosteroids is largely dominated by foreign companies, with Pfizer and Merck holding about half of the market share in 2023, highlighting a significant opportunity for domestic alternatives [5]. - Yuan Da Pharmaceutical's successful launch of the budesonide nasal spray, another first generic product, demonstrates the potential for domestic products to gain market share and disrupt foreign dominance [5][6]. Group 3: Product Pipeline and Innovation - Yuan Da Pharmaceutical has a comprehensive pipeline for allergic rhinitis treatments, including the upcoming Ryaltris® combination nasal spray, which is expected to meet the needs of patients with varying severity of allergic rhinitis [7][8]. - The company is also developing STC3141, an innovative product targeting sepsis, which has shown promising clinical results and addresses a significant unmet medical need in a market projected to reach 5.627 billion USD by 2030 [9]. - The focus on both self-developed and globally expanded research and development aims to solidify the company's position in the respiratory and critical care sectors [9].